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care resources. Data from 2001 to 2003 were collected from
the National Health Insurance Research Database (NHIRD),
containing health insurance enrollments and claims data
from over 97% of the Taiwanese population. Incident HZ
cases were identiﬁed through HZ diagnosis codes on health
care claims. Overall incidence rates were age-and sex-
adjusted. The cost of outpatient visits and hospitalizations
were obtained. The prescription patterns of antiviral and
neuropathic pain medications were examined. The data will
be presented in the meeting.
doi:10.1016/j.ijid.2008.05.068
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Herpes Zoster (HZ) and Post-herpetic Neuralgia (PHN):
Burden of Illness, Healthcare Utilization, and Costs; the
Thai Perspective
P. Pitisuttihum
Faculty of Tropical Medicine, Mahidol University, Bangkok,
Thailand
Background: Herpes Zoster is characterized by vesicular
cutaneous eruption with dermatomal distribution and is
mostly associated with debilitating pain and, later, post-
herpetic neuralgia, especially among patients aged more
than 50 years, despite early treatment with antiviral drugs.
This study aimed to measure the burden of disease, assess
the impact on quality of life, and determine healthcare
resource utilization and costs associated with HZ and PHN
in Thailand.
Methods: This was a prospective cohort study of patients
presenting with Zoster rash in 7 hospitals in Thailand. The
burden of illness and quality of life due to zoster- associated
pain were measured using the Zoster Brief Pain Inventory,
the Initial Zoster Impact Questionnaire, and the Euro-QoL.
Healthcare utilization, costs, and work-time and produc-
tivity lost due to both HZ and PHN, were measured by
simple questionnaire describing visits to physicians or clin-
ics, hospitalizations, use of other health-related services,
prescription medications, over-the-counter medications, as
well as diagnostic tests and procedures performed for the
current episode. Healthcare costs were estimated from
healthcare utilization data. Indirect costs were measured
by simple descriptive questionnaire, to determine time off
work taken by patients or caretakers, and lost income.
The above parameters were followed at each visit, at
days 0, 7, and months 1, 3, and 6.
Results: 180 patients with HZ were enrolled; 138 were
elderly (aged >50 years), 34 were HIV-infected, and 8 were
cancer patients. 160 and 104 patients completed month 3
and month 6, follow up respectively (April 10, 08). About
54% presented with rashes, primarily affected the thoracic
dermatome; 93.8% reported pain. The detailed results for
burden of illness, quality of life, and healthcare costs will
be presented.
doi:10.1016/j.ijid.2008.05.069
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2.001
he Changing Epidemiology of Fungal Infection: New
athogens and Problems
. Sathapatayavongs
Faculty of Medicine Ramathibodi Hospital, Mahidol Univer-
ity, Bangkok, Thailand
nvasive fungal infection is increasingly recognized as one of
he major causes of mortality and morbidity in healthcare.
his is due to the increase in susceptible hosts result-
ng from various factors such as intense antineoplastic and
mmunosuppressive agents, breakdown of anatomical barri-
rs, prolonged use of the intravascular catheter, parenteral
utrition, aggressive surgical procedures, broad-spectrum
ntibacterial agents, and HIV infection. Candida spp. and
spergillus spp. are the two most frequently pathogens
solated during the past 2 decades. Although both remain
ommonest pathogens, the changes in species isolated are
bserved. non-albicans Candida is increasing namely C.
labrata, C. krusei, C. tropicalis, C. parapsilosis, and apart
rom A. fumigatus, A. ﬂavus, A. niger, and A. terreus are
ncreasingly isolated. In the era of intensive chemotherapy
nd radiotherapy followed by the hematopoietic stem cell
ransplantation, Zygomycetes, Fusarium spp. Scedosporium
pp. emerge as very difﬁcult-to-treat pathogens. This may
e explained by the pattern of the use of antifungal agents:
uconazole, itraconazole, and amphotericin B. The selec-
ive pressure of these agents in the presence of prolonged
eutropenia and/or severe immunosuppression predispose
atients with these amphotericinB-resistant fungal infec-
ion. In AIDS patients, Cryptococcus neoformans is the most
ommon systemic fungal pathogen worldwide. In addition,
ndemic fungi such as Histoplasma capsulatum in USA and
enicillium marneffei in Thailand are common AIDS-related
ycoses. Another unique mycosis reported from Thailand
s pythiosis, the infection caused by Pythium insidiosum.
he most recognized form with high morbidity and mor-
ality is arteritis, commonly presented with limb gangrene,
neurysm and ultimately aortic rupture. Almost all patients
ave hemoglobinopathy-thallasemic syndrome and expose
o this organisms in the environment such as rice ﬁeld. Treat-
ent of this entity is still problematic since it is not a true
ungus and the response to the available antifungal agents
s unsatisfactory. Considering its habitat, it is likely that
ythiosis is underrecognized in the Southeast Asia region,
ne should be aware of this entity.
oi:10.1016/j.ijid.2008.05.070
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harmacodynamics of Antifungal Drugs: A Strategy to
ptimize Efﬁcacy
. AndesMadison, WI, USA
harmacodynamic studies examine the relationship between
rug pharmacokinetics and outcome. These investigations
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elp deﬁne the optimal drug exposure associated with treat-
ent efﬁcacy. The analyses of data from experimental
odels with different antifungal drug classes have identi-
ed distinct pharmacodynamic characteristics. Results from
hese models have been useful for deﬁning the relationship
etween antifungal exposures and efﬁcacy. More recently
linical data has become available allowing similar inves-
igation. These results of these studies have been similar
o those from experimental models and have cemented the
linical signiﬁcance of these pharmacodynamic concepts.
he analyses have been shown to be helpful for the design
f antifungal dosing intervals, choice of optimal dose levels,
herapeutic drug monitoring, and the development of sus-
eptibility breakpoints. Most of these preclinical and clinical
tudies have targeted therapeutic efﬁcacy against Candida
pecies. More recent studies have also considered other fun-
al pathogens and have begun to investigate the role of
nifungal pharmacodynamics and drug resistance develop-
ent. Although there remain many unanswered questions
egarding antifungal pharmacodynamics, available data sug-
est usefulness in the application of pharmacodynamics to
elp guide antifungal therapy.
oi:10.1016/j.ijid.2008.05.071
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ew Generation Triazoles: What Do They Offer and When
o We Need Them?
.C. Sorrell
University of Sydney, Westmead, Australia
oriconazole and posaconazole are the latest triazole drugs
o be marketed. Voriconazole was developed from ﬂucona-
ole by substituting a ﬂuoropyrimidine ring for one of the
zole groups to enhance the spectrum (to include Can-
ida krusei, ﬂuconazole-resistant C. glabrata, Aspergillus
pp, some Fusarium strains, Scedosporium apiospermum and
imorphic fungi such as Histoplasma capsulatum) and adding
he a-methyl group to provide fungicidal activity against
spergillus spp. in particular. Posaconazole is structurally
erived from itraconazole, with ﬂuorine replacing chlorine
ubstituents in the phenyl ring and hydroxylation of the tria-
olone side chain. These modiﬁcations enhance the potency
nd spectrum of antifungal activity to include the additional
pecies covered by voriconazole with the exception of Fusar-
um and in addition, the zygomycetes.
Randomised controlled clinical trials (RCTs) have iden-
iﬁed that voriconazole is the treatment of choice for
nvasive aspergillosis in the immunosuppressed. Efﬁcacy
as been demonstrated in candidiasis (including against
mall numbers of ﬂuconazole-resistant Candida infections),
n fusariosis, cryptococcosis and infections where cheaper
gents such as ﬂuconazole would be preferred. The major
rawbacks to replacing ﬂuconazole with voriconazole are
ts cost, adverse effects including a small incidence of
hotosensitivity, signiﬁcant drug interactions, and pharma-
okinetic issues, which may be resolved by therapeutic drug
onitoring in some settings.
Posaconazole has been subject to RCTs of its use
n prophylaxis against fungal infections in recipients of
aematopoietic stem cell transplants where, despite some
d
m
r
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esign ﬂaws, it has performed better than the comparator
egimen, and in HIV-associated oro-pharyngeal candidiasis.
t has been used as salvage therapy in other settings. The
ain drawbacks to widespread use of posaconazole include
ost, the lack of an intravenous formulation, reduced
ioavailability in the absence of food and lack of RCTs of
ts therapeutic use.
Conﬁrmation of improved clinical outcomes from the use
f either agent in combination therapy is yet to be obtained.
oi:10.1016/j.ijid.2008.05.072
2.004
nderstanding the Similarities and Differences of Existing
nd Emerging Echinocandins
.A. Slavin
Peter MacCallum Cancer Centre, Melbourne, Australia
he echinocandins, comprising caspofungin, micafungin and
nidulafungin, inhibit beta-(1,3)-glucan, Glucan is found in
ungal cell walls but not mammalian cells. As large highly
rotein bound molecules, none are orally bioavailable or
chieve levels in the CSF. The spectrum is consistent across
ll three agents with fungicidal activity against Candida, and
ungistatic activity against Aspergillus. The echinocandins
re not active against Cryptococcus,Scedosporium prolif-
cans or Zygomycetes. All are fungicidal against Candida
pecies although MIC90s vary slightly between agents with
he lowest MIC90s seen with anidulafungin, then micafungin,
nd caspofungin. However, it is not clear if these differ-
nces are clinically relevant. All have higher MIC90s for C.
arapsilosis, C. guilliermondii and C. lusitaniae compared
o other Candida spp. Although C. parapsilosis remains sus-
eptible despite a higher MIC90, resistance has emerged on
reatment. All may rarely cause histamine release with pru-
itis, rash and swelling. The differences between the agents
re shown in the table below:
oi:10.1016/j.ijid.2008.05.073
mergence of EV71 in the Asia Paciﬁc in the Last Decade
3.001
pidemiology of EV71 Outbreaks in the Region in the Past
ecade
. Kiyu1,∗, J. Cardosa2, K. Mohd-Noh1, R. Matbah1, C.H.
oi 1
Sarawak Health Department, Kuching, Malaysia
Institute of Health and Community Medicine, Universiti
alaysia Sarawak, Kuching, Malaysia
FMD: Current Knowledge and Challenges for Malaysia
nd the Asia Paciﬁc Region
Background: Hand, foot and mouth disease (HFMD), espe-
ially that caused by EV71 is an important re-emerging
isease in the Asia Paciﬁc region, with the potential to cause
assive outbreaks that can last for many months, and with
elatively high complications rates, and deaths.
Methods: A review of the ﬁrst-hand experiences gained
uring the control of the four major HFMD outbreaks in
